Stock Analysis
- United States
- /
- Personal Products
- /
- NasdaqCM:ELAB
Elevai Labs Second Quarter 2024 Earnings: US$0.077 loss per share (vs US$0.13 loss in 2Q 2023)
Elevai Labs (NASDAQ:ELAB) Second Quarter 2024 Results
Key Financial Results
- Revenue: US$605.5k (up 91% from 2Q 2023).
- Net loss: US$1.41m (loss widened by 10% from 2Q 2023).
- US$0.077 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Elevai Labs shares are down 12% from a week ago.
Risk Analysis
It is worth noting though that we have found 3 warning signs for Elevai Labs (2 are a bit concerning!) that you need to take into consideration.
Valuation is complex, but we're here to simplify it.
Discover if Elevai Labs might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:ELAB
Elevai Labs
A skincare development company, designs, manufactures, and markets skincare products in the United States.